Survival of drug-resistant metastatic papillary thyroid cancer under drug treated conditions via upregulation of sarco/endoplasmic reticulum calcium ATPase 1

Author:

Kim Seok-Mo1,Park Keunwan2,Yun Hyeok Jun1,Kim JungMin3,Choi Kyung Hwa4,Park Ki Cheong3

Affiliation:

1. Thyroid Cancer Center, Yonsei University College of Medicine

2. KIST Gangneung Institute of Natural Products

3. Yonsei University College of Medicine

4. CHA Bundang Medical Center, CHA University

Abstract

Abstract

Background: Papillary thyroid cancer (PTC) is a general thyroid cancer subtype, however, PTC may develop metastasize or become recurrent via anti-cancer drug resistance, rendering it practically incurable. Therefore, effective and reliable clinical approaches are urgently required. Methods: In this study, we demonstrated the coordinated upregulation of SERCA1 in metastatic PTC under anti-cancer drug treated conditions. SERCA1, in turn, is transcriptionally upregulated by CaMK2α via nuclear translocated NFκB. we propose a clinical approach that screens novel drug candidates based on target identification and numerous survival-involved gene validation in a patient-derived anti-cancer drug-resistant mediated lymph node metastatic PTC model. Results of lymph node metastatic PTC was compared to anti-cancer drug sensitive and main mass PTC on in vitro and in vivo model. Results: Consequently, we identified sarco/endoplasmic reticulum (ER) calcium ATPase 1 (SERCA1) in patient-derived metastatic PTC cells. SERCA1 was considerably increase under anti-cancer drug treated conditions such as sorafenib or lenvatinib by CaMK2α mediated nuclear translocated NFκB. SERCA is a critical component in cytosolic free calcium regulation. However, a cardiac dysfunction was inevitable in vivo because of non-specific inhibition of SERCA isoforms by conventional SERCA inhibitors. This study aimed to design a therapeutic approach with decrease of cardiac dysfunction via SERCA1-isoform specific inhibition by novel small molecules, CKP1 and CKP2 under severe ER stress condition in patient-derived metastatic papillary thyroid cancer. These novel SERCA1-specific inhibitors were remarkably increased tumor shrinkage in the patient-derived metastatic PTC xenograft tumor model without cardiac dysfunctionwhen combination treatment with anti-cancer drug, such as sorafenib and lenvatinib. Conclusively, these findings are clinically significant for novel combinatorial strategy development for effective refractory cancer cell treatments, especially in the case of anti-cancer drug-resistant mediated recurrent and metastatic cancer. Conclusions Here, we showed that increase of SERCA1 by CaMK2α mediated nuclear translocated NFκB was fundamentally responsible for cellular resistant for cytotoxic stress under sorafenib or levatinib treatment. These outcomes suggest progress for the novel combinatorial scheme that uses targeted therapy to treat malignant cancer cells, such as anti-cancer drug-resistant cancer cells.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3